A novel combinatorial cancer immunotherapy: Poly-IC and blockade of the PD-1/PD-L1 pathway

Toshihiro Nagato, Esteban Celis

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.

Original languageEnglish (US)
Article numbere28440
JournalOncoImmunology
Volume3
Issue number5
DOIs
StatePublished - Jan 1 2014

Keywords

  • Cancer immunotherapy
  • Colon cancer
  • Lung cancer
  • Melanoma
  • PD-1
  • PD-L1
  • Poly-IC

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'A novel combinatorial cancer immunotherapy: Poly-IC and blockade of the PD-1/PD-L1 pathway'. Together they form a unique fingerprint.

  • Cite this